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Because of its unique ability to exert long-lasting synaptic transmission blockade, botulinum
neurotoxin A (BoNT/A) is used to treat a wide variety of disorders involving peripheral nerve
terminal hyperexcitability. However, it has been a matter of debate whether this toxin has
central or peripheral sites of action.We employed a rat model in which BoNT/A1 or BoNT/A2
was unilaterally injected into the gastrocnemius muscle. On time-course measurements
of compound muscle action potential (CMAP) amplitudes after injection of BoNT/A1 or
BoNT/A2 at doses ranging from 1.7 to 13.6 U, CMAP amplitude for the ipsilateral hind leg
was markedly decreased on the first day, and this muscle flaccidity persisted up to the
14th day. Of note, both BoNT/A1 and BoNT/A2 administrations also resulted in decreased
CMAP amplitudes for the contralateral leg in a dose-dependent manner ranging from 1.7 to
13.6 U, and this muscle flaccidity increased until the fourth day and then slowly recovered.
Immunohistochemical results revealed that BoNT/A-cleaved synaptosomal-associated pro-
tein of 25 kDa (SNAP-25) appeared in the bilateral ventral and dorsal horns 4 days after
injection of BoNT/A1 (10 U) or BoNT/A2 (10 U), although there seemed to be a wider spread
of BoNT/A-cleaved SNAP-25 associated with BoNT/A1 than BoNT/A2 in the contralateral
spinal cord.This suggests that the catalytically active BoNT/A1 and BoNT/A2 were axonally
transported via peripheral motor and sensory nerves to the spinal cord, where they spread
through a transcytosis (cell-to-cell trafficking) mechanism. Our results provide evidence for
the central effects of intramuscularly administered BoNT/A1 and BoNT/A2 in the spinal
cord, and a new insight into the clinical effects of peripheral BoNT/A applications.
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INTRODUCTION
Botulinum neurotoxins (BoNTs) have traditionally been subdi-
vided into eight distinguishable serotypes (types A through H)
(1, 2). They are potent poisons that disrupt neurotransmission by
their proteolytic activity directed specifically at SNARE (soluble
N -ethylmaleimide-sensitive fusion protein attachment receptor)
proteins, which are essential for synaptic vesicle fusion and trans-
mitter release (1). Because of their long-lasting effects, botulinum
neurotoxin type A (BoNT/A) and BoNT/B are currently used in
a broad variety of therapeutic interventions (3, 4), such as for
spasticity (5), movement disorders (6), and pathological pain con-
ditions (7). BoNT/A is a metalloprotease that targets and cleaves
synaptosomal-associated protein of 25 kDa (SNAP-25), a member
of the SNARE family, thereby blocking the release of neuro-
transmitters (e.g., acetylcholine) from peripheral nerve terminals
(8–10). BoNT/A has been serologically classified into seven sub-
types (A1–A7), in which neurotoxin components vary in their
amino acid sequences (11–13), and its A1 subtype (BoNT/A1) is
currently used in clinics.
There is a traditional view that BoNT/A effects remain localized
to peripheral neuromuscular junctions near the toxin injection
site. However, it is becoming clear that some of BoNT/A1’s clin-
ical effects cannot be explained without assuming direct central
effects (4, 14, 15), and a potential central site of action has been a
matter of debate. In addition, the biological effects of the BoNT/A
subtypes other than BoNT/A1 are poorly understood. To address
these issues experimentally, we employed a rat model in which
either BoNT/A1 or BoNT/A2 was injected into the gastrocnemius
muscle of a hind leg. Our results provide evidence for the central
actions of catalytically active BoNT/A1 and BoNT/A2 via axonal
and transsynaptic transport from the periphery into the spinal
cord, where they spread via a transcytosis (cell-to-cell trafficking)
mechanism.
MATERIALS AND METHODS
ANIMALS AND ETHICS STATEMENT
Sprague Dawley rats aged 8 weeks (180–220 g; Charles River Labo-
ratories Japan, Yokohama, Japan) were used. The rats were housed
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in a controlled environment (25± 1°C, 50± 10% humidity,
and 12-h light/dark cycle) with access to food and tap water
ad libitum. All procedures involving experimental animals were
approved by the Ethical Review Committee of the University of
Tokushima and the Chemo-Sero-Therapeutic Research Institute
(KAKETSUKEN).
PURIFICATION OF TOXINS
BoNT/As were prepared employing a previously reported method
(16) with minor modifications (17). Briefly,Clostridium botulinum
type A strains 62A and Chiba-H, which belong to subtypes A1
and A2, respectively, were cultured in a PYG medium, contain-
ing 2% peptone, 0.5% yeast extract, 0.5% glucose, and 0.025%
sodium thioglycolate, at 30°C for 3 days. M toxin was purified from
the culture fluid by acid precipitation, protamine treatment, ion-
exchange chromatography, and gel filtration. Each subtype of M
toxin was adsorbed onto a DEAE Sepharose column equilibrated
with 10 mM phosphate buffer, and eluted with a 0–0.3 M NaCl
gradient buffer to separate BoNT/A and non-toxic components.
The different types of BoNT/A were stored at−70°C until use.
TOXIC ACTIVITY MEASUREMENTS
The toxic activities of BoNT/A1 and BoNT/A2 were determined
by employing the mouse intraperitoneal (i.p.) LD50 method, as
described previously (17). One mouse i.p. LD50 was defined as 1
unit (U).
MEASUREMENTS OF COMPOUND MUSCLE ACTION POTENTIALS
Compound muscle action potential (CMAP) measurements were
performed according to the method that we previously reported
(18). Rats were anesthetized with pentobarbital (Kyoritsu Seiyaku,
Tokyo, Japan) and fixated in the prone position. The electrode used
was an alligator clip lead wire (Viasys Healthcare, Tokyo, Japan)
attached to the skin. The stimulating electrodes (cathodes) were
placed on the skin over the fourth lumbar vertebra, and the stim-
ulating electrodes (anodes) were placed at 2 cm from the cathode
on the spinal column. The recording electrodes were placed on
the belly muscles of the left and right gastrocnemius muscles, the
reference recording electrodes on the left gastrocnemius tendons,
and the earth electrodes on the tail roots. Electric stimulation was
loaded at 25 mA for 0.2 ms, and the CMAP was measured using
a Nicolet Viking Quest EMG system (Viasys Healthcare, Tokyo,
Japan).
WESTERN BLOTS
Rats were sacrificed 4 days after stereotactic injection of BoNT/A1
(20 U) (n= 3) or saline (n= 3) into the unilateral striatum. The
striatal lysates were prepared and subjected to western blot analy-
sis, as previously reported by Yamamura et al. (19). Briefly, striatal
tissue samples were homogenized in ice-cold lysis buffer con-
taining 50 mM Tris–HCl buffer, pH 7.5, with 0.5 M NaCl, 0.5%
Triton X-100, 10 mM EDTA, 4 mM EGTA, 1 mM Na3VO4, 30 mM
Na2P2O7, 50 mM NaF, 0.1 mM leupeptin, 75µM pepstatin A,
50µg/ml trypsin inhibitor, 1 mM phenylmethanesulfonyl fluo-
ride, 100 nM calyculin A, and 1 mM dithiothreitol. After centrifu-
gation at 15,000 rpm for 10 min at 4°C, the protein lysates were
mixed with Laemmli buffer containing 63 mM Tris–HCl (pH 6.8),
2% sodium dodecylsulfate (SDS), 5% 2-mercaptoethanol, 2.5%
glycerol, and 0.01% bromophenol blue, and were then heated at
100°C for 5 min. Each sample, containing the same amount of
proteins (20µg/lane), was applied to a 12% SDS–polyacrylamide
gel electrophoresis (PAGE) followed by blotting onto a PVDF
membrane. The PVDF membranes were then incubated with the
desired primary antibodies. Monoclonal antibody (mAb) against
BoNT/A-cleaved SNAP-25 (1:1,000; GENTAUR Molecular, Santa
Clara, CA, USA) and polyclonal antibody against SNAP-25 protein
(1:10,000; GeneTex, Irvine, CA, USA) were used.
IMMUNOHISTOCHEMICAL STAINING AND DIGITAL IMAGING
Rats were sacrificed 4 days after unilateral injection of BoNT/A1
(10 U; n= 10), BoNT/A2 (10 U; n= 10), or saline (n= 3) into the
left gastrocnemius muscles. Deeply anesthetized rats were tran-
scardially perfused with 0.01 M phosphate-buffered saline (pH
7.4) (PBS), followed by 4% paraformaldehyde in 0.1 M phosphate
buffer (pH 7.4). After laminectomy, the spinal cords at the lum-
bosacral region were removed. They were post-fixed for 12 h in the
same fixative, and stored in a 10–30% sucrose gradient in 0.1 M
phosphate buffer at 4°C. Frozen sections with 25µm-thickness
were prepared on a cryostat, and then stored in PBS containing
0.05% NaN3 until use. For single antigen detection, free-floating
sections were pretreated with 1.0% hydrogen peroxide for 15 min.
As a blocking step, sections were then incubated in PBS contain-
ing 3% bovine serum albumin (BSA) and 50% normal goat serum
(NGS) for 3 h at room temperature. This was followed by incu-
bation in primary antibody diluted in PBS containing 3% BSA
and 50% NGS overnight at room temperature. The primary anti-
bodies used were mouse mAb against BoNT/A-cleaved SNAP-25
(1:5,000; GENTAUR Molecular) or rabbit polyclonal antibody
against SNAP-25 (1:20,000; GeneTex). Bound antibodies were
visualized with the Histofine Simple Stain Kit (Nichirei, Tokyo,
Japan) and the tyramide signal amplification (TSA) system with
Cyanine 3 or Fluorescein (Perkin Elmer LAS), according to the
methods reported previously (20, 21). For dual antigen detection,
the sections stained for BoNT/A-cleaved-SNAP-25 were incubated
in 0.1 M glycine–HCl (pH 2.2) at room temperature for 30 min.
After rinsing in PBS for 1 h, they were then incubated overnight
at room temperature in PBS containing 3% BSA and polyclonal
antibody against choline acetyltransferase (ChAT) (1:20,000; Mil-
lipore). The bound antibodies were detected by the Histofine
Simple Stain Kit (Nichirei) and the TSA system with Fluores-
cein (Perkin Elmer). Digital microscopy images were captured
using an Olympus BX51 microscope (Olympus, Tokyo, Japan),
imported into Adobe Photoshop CS4, and processed digitally for
adjustments of contrast, brightness, and color balance.
DENSITOMETRIC ANALYSIS
To estimate the density of BoNT/A-cleaved SNAP-25 labeling, the
immunostaining of the L5 spinal sections from rats that received
saline, BoNT/A1 or BoNT/A2 was simultaneously carried out in
parallel using the same protocols. By means of Meta Morph (Meta
Imaging Series 7.0; Molecular Devices, Tokyo, Japan), the optical
densities of immunoreactive products were measured on the raw
digital images of the ventral horns of the spinal cord. For each
animal that received saline (n= 3), BoNT/A1 (10 U; n= 6), or
Frontiers in Neurology | Movement Disorders June 2014 | Volume 5 | Article 98 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Koizumi et al. Central effects of botulinum toxins
BoNT/A2 (10 U; n= 6), measurements were made in the ventral
horns of three spinal sections.
STATISTICAL ANALYSIS
All experimental values were expressed as means± SD. Statistical
significance was evaluated by one-way ANOVA followed by the
Games–Howell post hoc test for pairwise comparisons, or by the
Mann–Whitney U -test. The significance level was set at P < 0.05.
RESULTS
BIOLOGICAL EFFECTS OF INTRAMUSCULARLY INJECTED BoNT/A1 AND
BoNT/A2
We used the CMAP measurements to determine the muscle flac-
cidity obtained with BoNT/As in rats. BoNT/A1 or BoNT/A2
toxin solution was injected into the left gastrocnemius mus-
cle (Figure 1A), and then the CMAP amplitudes of the left
(ipsilateral) and right (contralateral) hind legs were measured
over time for 14 days. On time-course measurement of CMAP
amplitudes after injection of BoNT/A1 (Figure 1B) or BoNT/A2
(Figure 1C) at lower doses ranging from 0.03 to 1.0 U, we found
that CMAP amplitude for the ipsilateral, but not contralateral,
hind leg decreased in a dose-dependent manner, and this muscle
flaccidity increased until the second day, after which it gradually
recovered.
With the same experimental protocols, time-course mea-
surements of CMAP amplitudes after injection of BoNT/A1
(Figure 2A) or BoNT/A2 (Figure 2B) at higher doses ranging
from 1.7 to 13.6 U showed that CMAP amplitude for the ipsilateral
hind leg markedly decreased on the first day, and this muscle flac-
cidity persisted up to the 14th day. Interestingly, either BoNT/A1
(Figure 2A) or BoNT/A2 (Figure 2B) administration also caused
decreased CMAP amplitudes for the contralateral legs in a dose-
dependent manner ranging from 1.7 to 13.6 U, and this muscle
flaccidity increased until the fourth day and then slowly recovered.
When equivalent doses were assessed, the degree of contralateral
muscle flaccidity obtained with BoNT/A2 seemed to be slightly
lower than that with BoNT/A1 at each time period. Thus, the bio-
logical effects of BoNT/A1 and BoNT/A2 were found in both hind
legs only when higher doses of the toxins were used, suggesting
that their effects could extend beyond the periphery to affect the
contralateral leg.
APPEARANCE OF BoNT/A-CLEAVED SNAP-25 IN THE SPINAL CORD
AFTER INTRAMUSCULAR INJECTION OF BoNT/A1 OR BoNT/A2
To test whether catalytically active BoNT/A1 and BoNT/A2
actually reach the spinal cord after peripheral intramuscu-
lar injection of the toxins, we performed immunohistochem-
ical examinations of spinal cord tissues 4 days after injection
FIGURE 1 | Compound muscle action potential measurements
following unilateral intramuscular injection of BoNT/A1 or BoNT/A2
at lower doses. (A) Experimental protocol. BoNT/A1 or BoNT/A2 was
unilaterally injected into the left gastrocnemius muscle, and the CMAP
amplitudes of both the hind legs were measured over time.
(B,C)Time-sequential changes in the CMAP amplitudes of left and right
hind legs after peripheral BoNT/A1 (B) or BoNT/A2 (C) injections at lower
doses of 0.03, 0.1, 0.3, or 1.0 U. Each point is the mean±SD (n=5).
*P <0.05 versus Day 0 in each dose of toxin; one-way ANOVA followed
by Games–Howell post hoc test.
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FIGURE 2 | Compound muscle action potential measurements
following unilateral intramuscular injection of BoNT/A1 or
BoNT/A2 at higher doses. Time-sequential changes in the CMAP
amplitudes of left and right hind legs after peripheral BoNT/A1 (A) or
BoNT/A2 (B) injections at higher doses of 1.7, 3.4, 6.8, or 13.6 U. Each
point is the mean±SD (n=5). #P <0.001, *P <0.05 versus Day 0 in
each dose of toxin; one-way ANOVA followed by Games–Howell
post hoc test.
of BoNT/A1 (10 U) or BoNT/A2 (10 U) toxin solution into
the left gastrocnemius muscles. For this purpose, we used
mAb against the synthetic peptide (EKADSNKTRIDEANQ)
(Figure 3A), which corresponds to the COOH-terminus of
BoNT/A-truncated SNAP-25 protein (22). Western blot analy-
sis (Figure 3B) revealed that the mAb used here reacted with
the cleaved form of SNAP-25 but not intact SNAP-25 protein.
Immunohistochemical results with the TSA techniques showed
significant immunoreactivity for SNAP-25 (Figure 3C), but not
cSNAP-25 (Figure 3D), in the spinal cord in the saline-treated
control rats. By contrast, we successfully detected cSNAP-25
immunoreactivity in the spinal cord in the toxin-treated rats, as
follows.
Figure 4 illustrates the distributional profiles of cSNAP-25
immunoreactivity in the spinal cord of rats that received BoNT/A1.
Macroscopic images of multiple segmental levels of the spinal
cord stained for cSNAP-25 are shown in Figures 4A,B. In accor-
dance with the fact that the L5 nerve dominantly innervates
the gastrocnemius muscle (23), strong immunoreactivity for
cSNAP-25 was observed in the ventral and dorsal horns of the
spinal cord at the segmental level of L5 ipsilateral to the peripheral
toxin injection site, but also to a lesser extent on the contralateral
side. Microscopic observations at higher magnification showed the
characteristic localization patterns of cSNAP-25 immunolabeling
in the anterior horn (lamina IX) of the spinal cord at L5, where
cSNAP-25-immunoreactive products appeared as tiny dots that
formed fibrous configurations and were numerously found on the
ipsilateral side (Figures 4C,E), but less numerously on the con-
tralateral side (Figures 4D,F). They appeared to delineate the cell
bodies of motoneurons labeled for ChAT, an enzyme that catalyzes
acetylcholine synthesis (Figures 4G,H). Additionally, cSNAP-25-
immunoreactive puncta were also found within the soma of some
motoneurons (Figure 4H). In the dorsal horns (Figure 4I), strong
cSNAP-25 immunolabeling was seen in the ipsilateral superficial
layers (lamina I–II), but also to a lesser extent on the contralateral
side.
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FIGURE 3 | Characterization of mAb against BoNT/A-cleaved
SNAP-25 (cSNAP-25). (A) Schematic representation of BoNT/A cleavage
site (arrow) in the SNAP-25 protein. Specific mAb was raised against the
synthetic peptide (EKADSNKTRIDEANQ), which corresponds to the
COOH-terminus of the cSNAP-25 protein. (B) Specificity of mAb against
cSNAP-25 as determined by western blot. Striatal lysates were prepared
from rats that received stereotactic injection of BoNT/A1 (20 U; BoNT) or
saline (S) into the striatum 4 days before sacrifice. They were then
subjected to 12% SDS-PAGE followed by western blot analysis with
anti-SNAP-25 or anti-cSNAP-25 antibody (see Materials and Methods).
Twenty micrograms of protein were loaded on each lane. Protein staining
(PS) and immunostaining for SNAP-25 and cSNAP-25 are shown. Small
arrow indicates SNAP-25 protein with an apparent molecular weight of
25 kDa. Large arrow indicates cSNAP-25 protein with an apparent
molecular weight of 24 kDa. Note that mAb against cSNAP-25 reacts
with the cleaved, but not non-cleaved, form of SNAP-25 protein.
(C) Multiple transverse spinal sections stained for SNAP-25 from
saline-treated rats. (D) Multiple transverse spinal cord sections stained
for cSNAP-25 from saline-treated rats (left panel), and their graded
color-converted images (right panel).
Figure 5 illustrates the distributional profiles of cSNAP-25
immunolabeling in the spinal cord of rats that received BoNT/A2.
Macroscopic images of multiple segmental levels of the spinal
cord stained for cSNAP-25 are shown in Figures 5A,B. As in
BoNT/A1-treated rats, strong immunoreactivity for cSNAP-25
was observed in the ventral and dorsal horns at the L5 spinal
segment ipsilateral to the peripheral toxin injection site, but
also to a lesser extent on the contralateral side. However, there
seemed to be a narrower spread of cSNAP-25 associated with
BoNT/A2 than BoNT/A1 in the contralateral spinal cord, par-
ticularly in the ventral horn. Microscopic observations on the
ventral horn (lamina IX) of the spinal cord at L5 showed that
cSNAP-25-immunoreactive products appeared as tiny dots that
formed fibrous configurations and that they were numerously
found on the ipsilateral side (Figures 5C,E), but only sparsely
on the contralateral side (Figures 5D,F). They often delineated
the cell bodies of motoneurons labeled for ChAT (Figures 5G,H),
and cSNAP-25-immunoreactive puncta were also found within
the soma of some motoneurons (Figure 5H). In the dorsal horns
(Figure 5I), strong cSNAP-25 immunolabeling was seen in the
ipsilateral superficial layers (lamina I/II), but also to a lesser extent
on the contralateral side.
To test our assumption that axonal and transsynaptic trans-
port of BoNT/A1 might be greater than that of BoNT/A2 (24),
we also carried out the densitometric analysis on the ventral
horns stained for cSNAP-25 at the L5 spinal segment in rats
that received BoNT/A1 or BoNT/A2 (Figure 6A). Optical density
measurements (Figure 6B) showed that in both the ipsilateral
and contralateral ventral horns, cSNAP-25 labeling in rats injected
with BoNT/A1 was significantly higher than that with BoNT/A2
(P < 0.05, Mann–Whitney U -test). Thus, it is likely that there
exists a wider spread of cSNAP-25 associated with BoNT/A1 than
BoNT/A2 in the spinal cord after peripheral muscular application
of the toxins.
DISCUSSION
In this study, we determined the functional consequences of injec-
tion of BoNT/A1 or BoNT/A2 into the gastrocnemius muscles
of the unilateral hind legs of rats, and the spinal distribution
of cSNAP-25 after this injection. CMAP measurements revealed
the novel finding that the injected BoNT/A1 or BoNT/A2 exerted
paralytic effects on both hind legs. The central actions of intramus-
cular application of BoNT/A are proposed to occur through axonal
and transsynaptic transport (14, 25–28). There is accumulating
evidence that like tetanus neurotoxin, BoNT/A can be transported
from peripheral neuromuscular junctions to the central nervous
system [for review see Ref. (14, 29)]. In a series of experiments
(17, 24), we also reported electrophysiological data indicating that
BoNT/A1 and BoNT/A2 can be carried from the peripheral to cen-
tral nervous system and vice versa by dual antero- and retrograde
axonal transport through either motor or sensory neurons. Indeed,
the present histological results revealed that cSNAP-25 appeared in
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FIGURE 4 | Appearance of cSNAP-25 in the spinal cord after
intramuscular injection of BoNT/A1. Immunohistochemical detection of
cSNAP-25 was carried out in the spinal cord 4 days after unilateral injection
of BoNT/A1 (10 U) into the left gastrocnemius muscle. (A,B) Displayed are
multiple transverse spinal cord sections stained for cSNAP-25 in rats that
received BoNT/A1 (A), and their graded color-converted images (B), in
which labeling intensity is indicated in a standard pseudocolor scale from
blue (lowest level) through green, yellow, red, and white (highest level).
(C,D) Photomicrographs of the ventral horns stained for cSNAP-25
ipsilateral (C) and contralateral (D) to peripheral toxin injection. Scale
bars=200µm. (E,F) Photomicrographs of the ventral horns (lamina IX)
stained for ipsilateral (E) and contralateral (F) to peripheral toxin injection.
Asterisks indicate spinal motoneurons. Scale bars=50µm.
(G) Photomicrograph of spinal motoneurons (arrows) doubly stained for
ChAT (green) and cSNAP-25 (red) ipsilateral to peripheral toxin injection.
Scale bar=25µm. (H) High power-magnified photomicrograph with a
longer exposure time showing a motoneuron (arrow) that exhibits
cSNAP-25-immunoreactive puncta in its soma. Scale bar=10µm.
(I) Photomicrograph of the dorsal horns labeled for cSNAP-25, which
contain lamina I and II (I/II). Scale bar=400µm.
the bilateral ventral and dorsal horns in distant spinal regions that
send efferents to the BoNT/A1- or BoNT/A2-injected muscles. As
shown in Figure 7, we suggest that catalytically active BoNT/A1 or
BoNT/A2 is axonally transported via peripheral motor and sensory
nerves and translocates to the spinal cord, where the toxin spreads
through a cell-to-cell trafficking mechanism. In accordance with
our previous data that axonal and transsynaptic transport of
BoNT/A1 is greater than that of BoNT/A2 (24), the present study
also showed a wider spread of cSNAP-25 associated with BoNT/A1
than BoNT/A2 in the contralateral spinal cord, particularly in the
ventral horn (see Figure 6). Although it remains unclear how
central synapses targeted by BoNT/A after axonal transport and
transcytosis are functionally altered, the central actions of trans-
ported BoNT/A could improve clinical symptoms by reinforcing
the efficacy of peripheral blockade. It is plausible that direct spinal
action of BoNT/A results in both motor terminal regeneration and
central synaptic reorganization after retrograde transport, so that
the supraspinal descending pathways can re-establish contact with
lower motor neurons in the spinal cord (15).
The present study showed that unilateral intramuscular
BoNT/A1 or BoNT/A2 injection resulted in not only ipsilateral but
also contralateral muscular flaccidity. Differential delivery routes
by which injected BoNT/A1 and BoNT/A2 affect contralateral
muscles have been suggested (17, 24) as BoNT/A1 is transported
almost equally to the contralateral muscles via neural pathways and
blood circulation, while BoNT/A2 is mainly transported to con-
tralateral muscles via the bloodstream (see Figure 7). This novel
evidence might corroborate the present finding that BoNT/A1
injection caused a significant decrease in CMAPs of contralat-
eral muscles associated with an abundance of cSNAP-25 in the
contralateral ventral horn, while BoNT/A2 injection did so in
despite of a paucity of cSNAP-25 in the contralateral ventral horn.
To further elucidate this hypothesis, more precise and quanti-
tative assessments of cSNAP-25 systemic distribution should be
performed.
The bilateral muscle relaxation effects seen after unilateral toxin
injection may lead to opposite clinical results depending on the
somatic symptom distribution of patients. For examples, unilat-
eral toxin injection could be beneficial in patients with bilateral
spasticity due to spinal cord injuries but harmful in patients with
unilateral spasticity due to forebrain cerebral apoplexy. Experi-
mental evidence from animal models has shown that BoNT/A1
can undergo axonal transport and transcytosis, which results in
central effects, particularly when high doses are used (14, 25,
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FIGURE 5 | Appearance of cSNAP-25 in the spinal cord after
intramuscular injection of BoNT/A2. Immunohistochemical detection of
cSNAP-25 was carried out in the spinal cord 4 days after unilateral injection
of BoNT/A2 (10 U) into the left gastrocnemius muscle. (A,B) Displayed are
multiple transverse spinal cord sections stained for cSNAP-25 in rats that
received BoNT/A2 (A), and their graded color-converted images (B), in
which labeling intensity is indicated in a standard pseudocolor scale from
blue (lowest level) through green, yellow, red, and white (highest level).
(C,D) Photomicrographs of the ventral horns stained for cSNAP-25
ipsilateral (C) and contralateral (D) to peripheral toxin injection. Scale
bars=200µm. (E,F) Photomicrographs of the ventral horns (lamina IX)
stained for ipsilateral (E) and contralateral (F) to peripheral toxin injection.
Asterisks indicate spinal motoneurons. Scale bars=50µm.
(G) Photomicrograph of spinal motoneurons (arrows) doubly stained for
ChAT (green) and cSNAP-25 (red) ipsilateral to peripheral toxin injection.
Scale bar=25µm. (H) High power-magnified photomicrograph with a
longer exposure time showing a motoneuron (arrow) that exhibits
cSNAP-25-immunoreactive puncta in its soma. Scale bar= 10µm.
(I) Photomicrograph of the dorsal horns labeled for cSNAP-25, which
contain lamina I and II (I/II). Scale bar=400µm.
FIGURE 6 | Densitometric analysis on the spinal ventral horns stained
for cSNAP-25. The optical densities of cSNAP-25-immunoreactive products
were measured in the spinal cord at the L5 segmental level 4 days after
unilateral injection of saline, BoNT/A1 (10 U) or BoNT/A2 (10 U) into the left
gastrocnemius muscle. (A)The scheme shows the transverse spinal cord
section at the L5 segment, in which measured areas in the bilateral ventral
horn are indicated by dashed open boxes colored in red. (B) Optical
densities of the ventral horns stained for cSNAP-25 in rats treated with
saline (n=3), BoNT/A1 (A1) (n=6), or BoNT/A2 (A2) (n=6). For each
animal, measurements were made in the ventral horns of three spinal cord
sections ipsilateral and contralateral to the toxin-injected sites. Values are
means±SD *P <0.05, A1 versus A2; Mann–Whitney U -test.
30). Indeed, we here showed that contralateral muscular flaccidity
following unilateral, peripheral toxin injection increased in a dose-
dependent manner in a dose-dependent manner ranging from 1.7
to 13.6 U. Although the biological effects obtained with the total
amount of injected toxin in rats could not easily compared with
those in humans, Caleo et al. (14) suggested that the dosage of
about 5 U in rats might be almost equivalent to a maximum dose
that can be used for the treatment of dystonia and spasticity in
patients. Keeping in mind the potential risk due to undesired con-
tralateral central effects of BoNT/A1, the dosage of BoNT/A1 used
should be carefully calibrated for each patient. This notion would
also apply in the future event of clinical use of BoNT/A2. On
one hand, as shown, BoNT/A2 might affect contralateral muscles
largely through the bloodstream (17, 24), we also posit that such
adverse effects of BoNT/A2 could be easily removed by the injec-
tion of A2-antitoxin, suggesting that the usage of BoNT/A2 would
be much safer than that of BoNT/A1.
BoNT/A1 can be effectively used to treat some pathological
pain conditions in patients (31). Recent reports have shown exper-
imental evidence for central antinociceptive action of peripherally
applied BoNT/A1 (32, 33). Our present results also revealed that
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FIGURE 7 | Possible mechanisms for the central actions of
intramuscularly injected BoNT/A in the spinal cord. Following unilateral
intramuscular BoNT/A1 (A) or BoNT/A2 (B) injection, the catalytically active
toxin can be axonally transported to the spinal cord through motor and
sensory nerves. Subsequently, the toxin can spread throughout the gray
matter of the spinal cord, including the bilateral ventral and dorsal horns, via a
transcytosis (cell-to-cell trafficking) mechanism by which a ligand penetrates
the neuron at one side, followed by its movement and release at the opposite
end, with possible uptake by second-order neurons. Differential delivery
routes by which injected BoNT/A1 and BoNT/A2 affect contralateral muscles
have also been proposed as BoNT/A1 (A) is transported almost equally to the
contralateral muscles via this neural pathways and the blood circulation, while
BoNT/A2 (B) is mainly transported to contralateral muscles via the
bloodstream only at higher doses. MN, motoneuron; DRG, dorsal root ganglia.
cSNAP-25 was highly concentrated in the superficial layer of
the ipsilateral dorsal horn at the L5 spinal segment after unilat-
eral peripheral injection of BoNT/A1 as well as BoNT/A2. This
novel finding could further our understanding of the antinoci-
ceptive mechanism(s) of BoNT/A. We speculate that BoNT/A
is axonally transported along the peripheral branch of nocicep-
tive sensory neurons (i.e., c-fiber) and then descends into the
dorsal horn, where the toxin might exert antinociceptive effects
by inhibiting the release of neurotransmitter and neuropeptides
(e.g., substance P) from the peripheral branch of primary sen-
sory neurons (34) (see Figure 7). Recent reports have also shown
bilateral antinociceptive effects of BoNT/A1 following unilateral,
peripheral toxin injection (32, 34, 35). As a possible mechanism by
which unilateral BoNT/A1 administration can exert contralateral
antinociceptive actions, we suggest that the toxin might spread
to contralateral dorsal horn neurons via a crossing fiber mech-
anism (36) and/or a transsynaptic cell-to-cell trafficking mech-
anism within the spinal cord. Our assumption is supported by
the present immunohistochemical finding that cSNAP-25 was
bilaterally distributed in the dorsal horns at the level of L5 (see
Figures 4 and 5). This is also confirmed by our previous func-
tional studies, which found that unilateral injection of BoNT/A1
to rat soleus muscle decreased the frequency of glycinergic spon-
taneous IPSCs in ipsi- and contralateral spinal second-order
sensory neurons (24). In addition, BoNT/A2 completely abol-
ished evoked EPSC projecting to spinal sacral dorsal commis-
sural nucleus neurons, one of second-order sensory neurons, in
rats (37).
In conclusion, we demonstrated central effects of intramuscu-
larly injected BoNT/A1 or BoNT/A2 in the rat spinal cord. Our
results may provide new insight into the clinical effects of periph-
erally applied BoNT/A in patients with pathological motor and
pain conditions.
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